The peroxidase, alkaline phosphatase, acid phosphatase, beta-glucuronidase and N-acetyl-beta-D-glucosaminidase activity was assessed using a semiquantitative cytochemical methods in peripheral blood neutrophils from 10 maintenance haemodialysed patients treated with recombinant human erythropoietin (rHu EPO) due to severe anaemia. The examination was performed immediately prior to rHu EPO treatment, after 10 weeks and 32 weeks of therapy. A statistically significant increase in the beta-glucuronidase and N-acetyl-beta-D-glucosaminidase activity was observed after 10 weeks, while all the enzymes studied except peroxidase showed a significant elevation of their activity after 32 weeks of the treatment as compared with the values obtained prior to therapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The role of erythropoietin to prevent red blood cell transfusion in a 2018-2020 two-center cohort of preterm infants.
Blood Transfus
July 2024
Department of Neonatology, Caen University Hospital, Université de Caen Normandie, UFR Médecine, Caen, France.
Background: Treatment with recombinant human erythropoietin (rHu-EPO) modestly prevented packed red blood cell transfusions (pRBCTs) in preterm infants in studies performed several years ago. In France, some neonatal units stopped using rHu-EPO, while others continued. The aim of this study was to explore the role of rHu-EPO in the prevention of pRBCTs in a recent cohort of preterm infants.
View Article and Find Full Text PDFCyclic thrombocytopenia related to erythropoietin-dependent anti-platelet anti-GPIV/IIIb antibody in hemodialysis.
J Nephrol
June 2022
University of Lyon, CarMeN, INSERM U1060, INSA de Lyon, Université Claude Bernard Lyon 1, INRA U1397, 69500, Bron, France.
Article Synopsis
- A 65-year-old patient on dialysis with a history of low platelet counts experienced recurring severe thrombocytopenia linked to injections of a medication called recombinant erythropoietin (rHu-EPO).
- Further investigation found that the patient's body developed an antibody that reacted with her platelets after receiving rHu-EPO, causing the platelet count issue.
- After stopping rHu-EPO and switching to a different treatment called roxadustat, the patient showed improvement in her hemoglobin and platelet levels.
Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin.
Ren Fail
December 2021
Department of Nephrology, Provincial Hospital affiliated to Shandong First Medical University, Jinan, PR China.
Introduction: A significant decrease in red blood cell (RBC) survival has been observed in patients with renal failure, which is supposed to contribute to renal anemia. The aim of this observational study was to determine RBC survival in hemodialysis (HD) patients treated with roxadustat or recombinant human erythropoietin (rhuEPO) compared with healthy persons.
Methods: RBC lifespan was measured by Levitt's CO breath test with newly developed automatic instrument ELS Tester.
Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis.
Blood Purif
March 2022
Department of Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Anemia is a common complication of chronic kidney disease (CKD). Recombinant human erythropoietin (rHu-EPO) is used extensively in patients with CKD. However, anti-erythropoietin (anti-EPO) antibody has been reported during rHu-EPO treatment, which causes pure red cell aplasia (PRCA).
View Article and Find Full Text PDFDoes subcutaneous administration of recombinant human erythropoietin increase thrombotic events in total hip arthroplasty? A prospective thrombelastography analysis.
J Orthop Surg Res
November 2020
Department of Orthopaedics, The Affiliated Hospital of Xuzhou Medical University, No. 99, Huaihai West Road, Xuzhou, Jiangsu Province, 221000, China.
Background: Anemia is one of severe complications in the perioperative period of total hip arthroplasty (THA). Erythropoietin (EPO) has been considered to improve patients' anemia state, but its efficiency and safety remains controversial.
Methods: A total of 152 patients who underwent total hip arthroplasty from January 2017 to March 2019 were randomized to 2 groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!